Volume 28, Number 6—June 2022
Research
Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo
Figure 2

Figure 2. Days to first negative test result since symptom onset among patients who survived, stratified by vaccination status, n = 144, for impact of recombinant vesicular stomatitis virus–Zaire Ebola virus vaccination on Ebola virus disease illness and death, Democratic Republic of the Congo. Horizontal lines within boxes indicate medians; error bars indicate interquartile ranges, p<0.0001, by Wilcoxon rank sum test.
Page created: March 31, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.